scholarly journals Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial1

2000 ◽  
Vol 85 (5) ◽  
pp. 1895-1900 ◽  
Author(s):  
Ignac Fogelman ◽  
Claude Ribot ◽  
Roger Smith ◽  
Dominique Ethgen ◽  
Earl Sod ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Low Bone Mass ◽  
Double Blind ◽  
Double Blind Placebo

Risedronate Reverses Bone Loss in Postmenopausal Women With Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial

2000 ◽  
Vol 55 (10) ◽  
pp. 630-632
Author(s):  
Ignac Fogelman ◽  
Claude Ribot ◽  
Roger Smith ◽  
Dominique Ethgen ◽  
Earl Sod ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Controlled Trial ◽  
Low Bone Mass ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways

2019 ◽  
Vol 10 (10) ◽  
pp. 6556-6567 ◽  
Author(s):  
Haiming Jin ◽  
Zhenxuan Shao ◽  
Qingqing Wang ◽  
Jiansen Miao ◽  
Xueqin Bai ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Bone Quality ◽  
Progressive Disease ◽  
Erk Signaling ◽  
Low Bone Mass

Postmenopausal osteoporosis (PMO) is a progressive disease occurring in elderly postmenopausal women that is characterized by low bone mass and impaired bone quality.

Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years

1997 ◽  
Vol 7 (2) ◽  
pp. 119-125 ◽  
Author(s):  
S. Adami ◽  
L. Bufalino ◽  
R. Cervetti ◽  
C. Di Marco ◽  
O. Di Munno ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Low Bone Mass ◽  
Radial Bone
Sign in / Sign up

Export Citation Format

Share Document